Johnson & Johnson has agreed to pay $5.5bn to settle a large wave of US lawsuits tied to its talc-based baby powder. The cases, numbering nearly 70,000, claim the product was linked to ovarian cancer.
The proposed deal is aimed at resolving years of litigation over the company’s discontinued talc baby powder. Plaintiffs have argued that long-term use of the product caused serious illness, while the legal fight has become one of the most closely watched corporate liability disputes in the United States.
The settlement figure marks a major step in J&J’s effort to contain the financial and legal fallout from the talc claims. Because the lawsuits involve a very large group of claimants, the agreement is significant both for the company and for people seeking compensation over the cancer allegations.
The case has drawn wide attention because it combines consumer product safety concerns with a multibillion-dollar legal strategy. With this $5.5bn talc settlement offer, Johnson & Johnson is seeking to move toward closure in one of the biggest product-related court battles facing a major healthcare company.
